This episode explores the spin-out of Pentixapharm, a German biotech company focused on developing radiopharmaceuticals for cancer and hypertension. Andreas Eckert shares insights on the company’s origin, clinical pipeline, and its recent acquisition of Glycotope’s target discovery unit.

Key Points:

Pentixapharm is advancing next-gen radiopharmaceuticals targeting CXCR4 and beyond. With late-stage clinical trials and expanded R&D capabilities, the company is poised to make an impact in cancer and cardiovascular care.

• From Supply Chain to Spin-Out: Originally a subsidiary of Eckert & Ziegler, a radioisotope supplier, Pentixapharm is spinning out to avoid competing with its clients. The new company will independently develop radiopharmaceuticals using its advanced CXCR4-targeting platform.
• CXCR4- A Powerful Target for Cancer: Pentixapharm’s lead compounds target the CXCR4 receptor, overexpressed in blood cancers. These agents show promise in both diagnostics and therapeutics, including a Phase 1/2a trial and two active Phase 3 diagnostic programs in Europe and the U.S.
• Transforming Hypertension Diagnosis: The company is also developing a PET imaging agent for diagnosing primary aldosteronism, a treatable cause of high blood pressure. The non-invasive scan could replace complex biopsies, helping millions receive better-targeted therapy.
• Boosted by Glycotope’s Expertise: The acquisition of Glycotope’s target discovery division brings in a team skilled in antibody development, enhancing Pentixapharm’s ability to diversify beyond CXCR4 and into new therapeutic areas like autoimmune diseases.
• Focused Future with Big Pharma Potential: Rather than commercializing its own products, Pentixapharm plans to advance its pipeline to key clinical milestones before partnering with larger pharmaceutical companies—positioning itself as a research-driven innovator in a booming radiopharma sector.